Skip to main content
. 2022 Jan 10;83(4):346–355. doi: 10.1016/j.humimm.2022.01.004

Fig. 6.

Fig. 6

Molecular docking of BsAb with its target. (A) Spike Glycoprotein docking with CDRs of Regdanvimab arm of BsAbs and their interaction has shown in the box. (B) DPP4 docking with CDRs of the Begelomab arm of BsAb, and their interaction has shown in stick form in the box as interface residue interaction.